To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to healthcare and ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...

Here are the most important news items that investors need to start their trading day: ...

South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over their insulin pen market practices, amid growing concerns about ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...